Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
5E Advanced Materials (ASX:5EA) filed a foundational patent application with the US Patent and Trademark Office for its proprietary closed-loop in-situ leach boron mining and production process.
Boss Energy (ASX:BOE) has concluded its Honeymoon review and announced a new feasibility study.
Buru Energy (ASX:BRU) has provided an update on its 100% owned Rafael Gas Project.
Renegade Exploration (ASX:RNX) has signed a lease and option agreement granting it exclusive rights to explore and potentially acquire the Rooster Hill Monazite Project.
Bapcor (ASX:BAP) announced that Chris Wilesmith will succeed Angus McKay as CEO and Managing Director.
APA Group (ASX:APA) has announced the execution of a binding agreement to sell its 20% equity stake in GDI.
Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.
The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.
NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.
Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.
Warner Bros. Discovery (NASDAQ:WBD) has announced that its Board of Directors has unanimously rejected the tender offer launched by Paramount Skydance (NASDAQ:PSKY) on December 8, 2025.
